Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology · Progressive Supranuclear Palsy - Richardson Syndrome

Biology & Diagnosis: Why PSP is Not Parkinson's

At a Glance

Progressive Supranuclear Palsy (PSP-RS) is distinctly different from Parkinson's disease. PSP is driven by the buildup of tau protein rather than alpha-synuclein, leading to different symptoms like early backward falls, neck stiffness, vertical gaze palsy, and a poor response to levodopa.

While Progressive Supranuclear Palsy - Richardson Syndrome (PSP-RS) is often called an “atypical parkinsonism,” it is biologically and clinically distinct from Parkinson’s disease (PD). Understanding these differences is essential for ensuring you receive the correct support and can plan for the future with clarity.

The Biological “Fingerprint”

The most fundamental difference between these two conditions lies in the specific proteins that build up in the brain.

  • PSP-RS (4R Tauopathy): In PSP-RS, a protein called tau misfolds and forms toxic clumps [1]. Specifically, it is the 4-repeat (4R) version of this protein that accumulates in the midbrain and other deep brain structures [2][3].
  • Parkinson’s Disease (Alpha-synucleinopathy): In contrast, Parkinson’s is driven by the buildup of a different protein called alpha-synuclein, which forms “Lewy bodies” primarily in the substantia nigra [4].

Because the “culprit” protein is different, the treatments that work for one often do not work for the other.

Why Parkinson’s Meds Usually Fail

The most common treatment for Parkinson’s is levodopa, a drug that replaces dopamine in the brain. In Parkinson’s, the brain’s dopamine-producing cells are the main target of the disease, so adding dopamine back in often works wonders [5].

In PSP-RS, however, the damage is more widespread. The tau protein damages not only the cells that make dopamine but also the “receiver” cells that use it [6][7]. Because the receivers are damaged, adding more dopamine (via levodopa) is like trying to make a phone call to a broken telephone—the signal is there, but the receiver cannot pick it up [5][6].

Clinical Differences: PSP-RS vs. Parkinson’s

Doctors use several key clinical signs to differentiate these two conditions, especially in the early stages:

Feature PSP-Richardson Syndrome Parkinson’s Disease
Primary Rigidity Axial Rigidity: Stiffness is centered in the neck and trunk [8]. Limb Rigidity: Stiffness is usually felt in the arms and legs [8].
Timing of Falls Early: Frequent backward falls occur within the first 1–3 years [9]. Late: Falls usually do not occur until many years after diagnosis [10].
Eye Movements Vertical Gaze Palsy: Difficulty looking up or down is a hallmark sign [11]. Usually normal in the early stages [11].
Medication Response Poor or very short-lived response to levodopa [12]. Robust, sustained response to levodopa [7].

The Role of MRI: The “Hummingbird Sign”

While a diagnosis is primarily based on a physical exam, specialized MRI imaging can provide strong supporting evidence. Doctors look for a specific pattern of shrinking (atrophy) in the brainstem.

  • The Hummingbird Sign: On a side-view MRI of a healthy brain, the midbrain and the pons (two parts of the brainstem) have a proportional relationship. In PSP-RS, the midbrain shrinks significantly while the pons remains a normal size [13]. The shrunken midbrain forms the “head and beak,” while the normal pons forms the “body,” creating a silhouette that remarkably resembles a hummingbird [13][14].
  • The M/P Ratio: Radiologists calculate the midbrain-to-pons (M/P) ratio. A low ratio is a highly specific “biomarker” that helps confirm a PSP-RS diagnosis and rules out Parkinson’s [15][16].

This imaging “fingerprint” is often visible even before all the clinical symptoms are fully present, making it a vital tool for modern diagnosis [17].

Common questions in this guide

Why doesn't levodopa work well for progressive supranuclear palsy?
In Parkinson's disease, levodopa helps replace missing dopamine. In PSP, the disease damages the brain cells that receive dopamine signals, making levodopa largely ineffective since the brain cannot properly process the medication.
What is the hummingbird sign on a brain MRI?
The hummingbird sign is a specific pattern seen on a brain MRI where the midbrain shrinks but the pons remains normal in size. This creates a silhouette resembling a hummingbird and is a strong indicator of PSP rather than Parkinson's disease.
How do the symptoms of PSP differ from Parkinson's in the early stages?
Early signs of PSP often include frequent backward falls within the first few years, stiffness primarily in the neck and trunk, and difficulty looking up or down. In contrast, Parkinson's typically features limb stiffness and falls usually happen much later in the disease.
Is progressive supranuclear palsy a type of Parkinson's disease?
No, while PSP is considered an atypical parkinsonism because it shares some movement symptoms, it is a biologically distinct disease. It is caused by the buildup of a different toxic protein called tau and affects different parts of the brain.
What does it mean that PSP is a 4R tauopathy?
A 4R tauopathy means that a specific version of the tau protein is misfolding and clumping together in the brain. This toxic buildup is the underlying biological cause of the damage seen in progressive supranuclear palsy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can you show me the midbrain and pons on my MRI and explain if the 'hummingbird sign' is present?
  2. 2.Since my response to levodopa has been poor, are there other medications that can help manage my stiffness or balance?
  3. 3.What specific signs in my eye movement exam distinguish my condition from Parkinson's disease?
  4. 4.Does the fact that my falls started early in my illness confirm a PSP-RS diagnosis over Parkinson's?
  5. 5.How does the 4R tau pathology in my brain affect which clinical trials I might be eligible for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

    Boxer AL, Yu JT, Golbe LI, et al.

    The Lancet. Neurology 2017; (16(7)):552-563 doi:10.1016/S1474-4422(17)30157-6.

    PMID: 28653647
  2. 2

    Probable 4-Repeat Tauopathy Criteria Predict Brain Amyloid Negativity, Distinct Clinical Features, and FDG-PET/MRI Neurodegeneneration Patterns in Corticobasal Syndrome.

    Parmera JB, de Godoi Carneiro C, de Almeida IJ, et al.

    Movement disorders clinical practice 2024; (11(3)):238-247 doi:10.1002/mdc3.13959.

    PMID: 38155526
  3. 3

    DNA methylation patterns in the frontal lobe white matter of multiple system atrophy, Parkinson's disease, and progressive supranuclear palsy: a cross-comparative investigation.

    Murthy M, Fodder K, Miki Y, et al.

    Acta neuropathologica 2024; (148(1)):4 doi:10.1007/s00401-024-02764-4.

    PMID: 38995454
  4. 4

    Long-standing preservation of levodopa response in progressive supranuclear palsy.

    Sano T, Mizutani M, Ishihara T, et al.

    Journal of the neurological sciences 2024; (466()):123203 doi:10.1016/j.jns.2024.123203.

    PMID: 39260141
  5. 5

    Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses.

    Ye L, Sani SS, Veith Sanches L, et al.

    Brain sciences 2024; (14(10)) doi:10.3390/brainsci14100991.

    PMID: 39452005
  6. 6

    Pathomechanisms of cognitive impairment in progressive supranuclear palsy.

    Jellinger KA

    Journal of neural transmission (Vienna, Austria : 1996) 2023; (130(4)):481-493 doi:10.1007/s00702-023-02613-w.

    PMID: 36862189
  7. 7

    The Progressive Supranuclear Palsy: Past and Present Aspects.

    Parthimos TP, Schulpis KH

    Clinical gerontologist 2020; (43(2)):155-180 doi:10.1080/07317115.2019.1694115.

    PMID: 31752626
  8. 8

    Tau in Atypical Parkinsonisms: A Meta-Analysis of in Vivo PET Imaging Findings.

    Mena AM, Chen R, Graff-Guerrero A, et al.

    Movement disorders clinical practice 2023; (10(12)):1725-1737 doi:10.1002/mdc3.13885.

    PMID: 38094644
  9. 9

    Interventions in progressive supranuclear palsy.

    Koros C, Stamelou M

    Parkinsonism & related disorders 2016; (22 Suppl 1()):S93-5.

    PMID: 26459661
  10. 10

    Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting.

    Cooperrider J, Bluett B, Jones SE

    Clinical parkinsonism & related disorders 2020; (3()):100033 doi:10.1016/j.prdoa.2020.100033.

    PMID: 34316619
  11. 11

    Refining initial diagnosis of Parkinson's disease after follow-up: A 4-year prospective clinical and magnetic resonance imaging study.

    Quattrone A, Morelli M, Vescio B, et al.

    Movement disorders : official journal of the Movement Disorder Society 2019; (34(4)):487-495 doi:10.1002/mds.27621.

    PMID: 30759325
  12. 12

    Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect.

    Nasri A, Sghaier I, Neji A, et al.

    Journal of movement disorders 2024; (17(2)):158-170 doi:10.14802/jmd.23178.

    PMID: 38290492
  13. 13

    Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy.

    Owens E, Krecke K, Ahlskog JE, et al.

    Parkinsonism & related disorders 2016; (28()):107-11.

    PMID: 27160570
  14. 14

    'Hummingbird' Sign in a Patient with Guam Parkinsonism-Dementia Complex.

    Yeo T, Tan LC

    Journal of movement disorders 2017; (10(3)):145-148 doi:10.14802/jmd.17025.

    PMID: 28782342
  15. 15

    Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.

    Zanigni S, Calandra-Buonaura G, Manners DN, et al.

    NeuroImage. Clinical 2016; (11()):736-742 doi:10.1016/j.nicl.2016.05.016.

    PMID: 27330973
  16. 16

    The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasias.

    Silsby M, Tweedie-Cullen RY, Murray CR, et al.

    European journal of neurology 2017; (24(7)):956-965 doi:10.1111/ene.13314.

    PMID: 28510312
  17. 17

    Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.

    Ahn JH, Kim M, Kim JS, et al.

    Parkinsonism & related disorders 2019; (66()):80-86 doi:10.1016/j.parkreldis.2019.07.009.

    PMID: 31307918

This page explains the biological and diagnostic differences between PSP-RS and Parkinson's disease for educational purposes only. Always consult your neurologist for an accurate diagnosis and personalized treatment plan.

Get notified when new evidence is published on Classic progressive supranuclear palsy syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.